168 related articles for article (PubMed ID: 34462295)
1. Managing multiple myeloma.
Lee AS; Tsang RY; Sandhu I
CMAJ; 2021 Aug; 193(34):E1349. PubMed ID: 34462295
[No Abstract] [Full Text] [Related]
2. Updates in the treatment of multiple myeloma.
Berenson JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
[No Abstract] [Full Text] [Related]
3. Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Terpos E; Dimopoulos MA
Lancet Oncol; 2010 Oct; 11(10):913-4. PubMed ID: 20863760
[No Abstract] [Full Text] [Related]
4. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
5. The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.
Tariman JD; Estrella SM
Oncol Nurs Forum; 2005 Nov; 32(6):E127-38. PubMed ID: 16270103
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
[No Abstract] [Full Text] [Related]
7. Real-world renal function among patients with multiple myeloma in the United States.
Mikhael J; Singh E; Rice MS
Blood Cancer J; 2021 May; 11(5):99. PubMed ID: 34021119
[No Abstract] [Full Text] [Related]
8. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
9. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
10. [Treatment for multiple myeloma: current status and future strategy in Japan].
Iida S
Rinsho Ketsueki; 2008 Oct; 49(10):1368-73. PubMed ID: 18833921
[No Abstract] [Full Text] [Related]
11. Prevention and treatment of myeloma bone disease.
Terpos E; Kastritis E; Dimopoulos MA
Curr Hematol Malig Rep; 2012 Dec; 7(4):249-57. PubMed ID: 22941027
[TBL] [Abstract][Full Text] [Related]
12. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
McCarthy PL
J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: future directions in autologous transplantation and novel agents.
Hari PN; McCarthy PL
Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S20-5. PubMed ID: 23290439
[No Abstract] [Full Text] [Related]
15. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
16. Controversies in multiple myeloma: to transplant or not?
Preeshagul IR; Van Besien K; Mark TM
Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
[TBL] [Abstract][Full Text] [Related]
17. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Anderson K; Ismaila N; Kyle RA
J Oncol Pract; 2018 Apr; 14(4):266-269. PubMed ID: 29517956
[No Abstract] [Full Text] [Related]
18. The role of bisphosphonates in multiple myeloma.
Levy J; Roodman GD
Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
[TBL] [Abstract][Full Text] [Related]
19. Orthopaedics: Structural support.
Berglund J
Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
[No Abstract] [Full Text] [Related]
20. How I treat elderly patients with myeloma.
Mehta J; Cavo M; Singhal S
Blood; 2010 Sep; 116(13):2215-23. PubMed ID: 20644120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
